TaiwanJ Pharmaceuticals Co., Ltd. (TPEX:6549)
Taiwan
· Delayed Price · Currency is TWD 7.80
-0.01 (-0.13%)
Apr 29, 2026, 2:00 PM CST
TaiwanJ Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | - | - | 22.74 | 15.36 | 22.06 | Upgrade
|
| Revenue Growth (YoY) | - | - | 48.11% | -30.38% | - | Upgrade
|
| Cost of Revenue | - | - | - | 75.28 | - | Upgrade
|
| Gross Profit | - | - | 22.74 | -59.92 | 22.06 | Upgrade
|
| Selling, General & Admin | 14.51 | 15.64 | 15.38 | 12.98 | 14.05 | Upgrade
|
| Research & Development | 10.7 | 11.31 | 13.97 | 12.74 | 17.73 | Upgrade
|
| Operating Expenses | 25.21 | 26.96 | 29.35 | 36.47 | 31.78 | Upgrade
|
| Operating Income | -25.21 | -26.96 | -6.61 | -96.39 | -9.73 | Upgrade
|
| Interest Expense | -0.05 | -0.01 | -0.02 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 1.64 | 2.1 | 2.52 | 0.49 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.72 | 2.53 | 0.33 | 3.29 | -0.62 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | - | 0.01 | 0.16 | - | Upgrade
|
| EBT Excluding Unusual Items | -24.34 | -22.34 | -3.77 | -92.47 | -10.32 | Upgrade
|
| Pretax Income | -24.34 | -22.34 | -3.77 | -92.47 | -10.32 | Upgrade
|
| Income Tax Expense | - | - | 2.27 | - | 2.11 | Upgrade
|
| Net Income | -24.34 | -22.34 | -6.05 | -92.47 | -12.42 | Upgrade
|
| Net Income to Common | -24.34 | -22.34 | -6.05 | -92.47 | -12.42 | Upgrade
|
| Shares Outstanding (Basic) | 80 | 77 | 75 | 75 | 75 | Upgrade
|
| Shares Outstanding (Diluted) | 80 | 77 | 75 | 75 | 75 | Upgrade
|
| Shares Change (YoY) | 4.68% | 1.89% | - | 0.03% | 6.07% | Upgrade
|
| EPS (Basic) | -0.30 | -0.29 | -0.08 | -1.23 | -0.17 | Upgrade
|
| EPS (Diluted) | -0.30 | -0.29 | -0.08 | -1.23 | -0.17 | Upgrade
|
| Free Cash Flow | -24.46 | -22.62 | -2.26 | -22.3 | -10.05 | Upgrade
|
| Free Cash Flow Per Share | -0.30 | -0.30 | -0.03 | -0.30 | -0.13 | Upgrade
|
| Gross Margin | - | - | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | - | - | -29.07% | -627.77% | -44.09% | Upgrade
|
| Profit Margin | - | - | -26.59% | -602.20% | -56.32% | Upgrade
|
| Free Cash Flow Margin | - | - | -9.95% | -145.22% | -45.56% | Upgrade
|
| EBITDA | -24.37 | -25.76 | -5.29 | -20.49 | -9.12 | Upgrade
|
| EBITDA Margin | - | - | -23.28% | -133.41% | -41.37% | Upgrade
|
| D&A For EBITDA | 0.84 | 1.19 | 1.32 | 75.91 | 0.6 | Upgrade
|
| EBIT | -25.21 | -26.96 | -6.61 | -96.39 | -9.73 | Upgrade
|
| EBIT Margin | - | - | -29.07% | - | -44.09% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.